ReviewFrontiers in pharmacology2023
Icariin as a potential anticancer agent: a review of its biological effects on various cancers.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Effect of icariin on ovarian cancer: a combined network pharmacology and meta-analysis ofFrontiers in pharmacology · 2024Pooled it
- Integrated Multi-Omics and Single-Cell Analyses Implicate NOX4 as an Icariin-Associated Oxidative Stress Regulatory Node in Gastric Cancer.Food science & nutrition · 2026Article
- KAN-PROSPECT: a Kolmogorov-Arnold Networks-integrated framework for predicting the effects and adverse reactions of natural products via transfer learning.Scientific reports · 2026Article
- Review
- Icariin Against Neurodegeneration: A Focus in Cell Death Pathways.International journal of molecular sciences · 2026Review
- Article
- Icaritin and lenvatinib treatment for unresectable localized progressive pancreatic cancer: a report of six cases.Annals of medicine · 2025Article
- An exhaustive examination of the research progress in identifying potential JAK inhibitors from natural products: a comprehensive overview.Chinese medicine · 2025Review
- Enhanced Stability of Multi-Functionalized Gold Nanoparticles and Potential Anticancer Efficacy on Human Cervical Cancer Cells.Biomedicines · 2025Article
- Computer-Aided Discovery of Natural Compounds Targeting the ADAR2 dsRBD2-RNA Interface and Computational Modeling of Full-Length ADAR2 Protein Structure.International journal of molecular sciences · 2025Article
- Osteogenic action of the natural plant material icariin and its potential use in biomedical tissue engineering.American journal of translational research · 2025Review
- Therapeutic Effects and Mechanisms of Icaritin in Parkinson's Disease.Current pharmaceutical design · 2025Review
- Unveiling the Therapeutic Potential of Trigonelline: A Promising Approach in Cancer Prevention and Treatment.Anti-cancer agents in medicinal chemistry · 2025Review
- Icariin as a Treatment Proposal in Mammalian Reproduction.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Icariin accelerates bone regeneration by inducing osteogenesis-angiogenesis coupling in rats with type 1 diabetes mellitus.World journal of diabetes · 2024Article
- An updated review summarizing the anticancer potential of flavonoids via targeting NF-kB pathway.Frontiers in pharmacology · 2024Review
- Role of flavonoids in inhibiting triple-negative breast cancer.Frontiers in pharmacology · 2024Review
- Unraveling the Neuroprotective Effect of Natural Bioactive Compounds Involved in the Modulation of Ischemic Stroke by Network Pharmacology.Pharmaceuticals (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous chemical compounds used in cancer treatment have been isolated from natural herbs to address the ever-increasing cancer incidence worldwide. Therein is icariin, which has been extensively studied for its therapeutic potential due to its anti-inflammatory, antioxidant, antidepressant, and aphrodisiac properties. However, there is a lack of comprehensive and detailed review of studies on icariin in cancer treatment. Given this, this study reviews and examines the relevant literature on the chemopreventive and therapeutic potentials of icariin in cancer treatment and describes its mechanism of action. The review shows that icariin has the property of inhibiting cancer progression and reversing drug resistance. Therefore, icariin may be a valuable potential agent for the prevention and treatment of various cancers due to its natural origin, safety, and low cost compared to conventional anticancer drugs, while further research on this natural agent is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.